Pancreatic Cancer Clinical Trial
Official title:
A Safety and Preliminary Efficacy Study of the Oral Live Biotherapeutic MRx0518 With Hypofractionated Preoperative Radiation for Resectable Pancreatic Cancer
Verified date | June 2023 |
Source | 4D pharma plc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single center, open-label, phase I study to evaluate the safety and preliminary efficacy of MRx0518 with preoperative hypofractionated radiation in 15 patients with resectable pancreatic cancer. Subjects will take MRx0518 daily for one week prior to the start of radiation therapy, throughout radiation and until surgical resection of the tumour.
Status | Terminated |
Enrollment | 13 |
Est. completion date | May 8, 2023 |
Est. primary completion date | May 8, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient has signed informed consent and is willing to comply with the protocol - Cytologic or biopsy confirmed adenocarcinoma of the pancreas - TNM stage: Tx, T1-4, N0-1 or Nx, M0 - Potentially resectable pancreatic cancer defined as no extra-pancreatic disease, no evidence of tumor extension to the celiac axis, common hepatic artery and superior mesenteric artery, and no evidence of deformity of the superior mesenteric vein or superior mesenteric portal vein confluence - No evidence of distant metastases either prior to or after induction chemotherapy - Able to comply with instructions required for radiation therapy - Age 18 years or older - Completion of 2-6 months of standard induction chemotherapy (mFOLFIRINOX, gemcitabine and nab-paclitaxel or other) - Eastern Cooperative Oncology Group Score 0, 1 or 2 - Adequate haematologic function (absolute neutrophil count =1500mm3; haemoglobin =8.0 g/dL; platelet count =50000mm3) - Adequate renal and liver function (creatinine = 1.5 x upper limit of normal; total bilirubin = 1.5 x upper limit of normal; aspartate aminotransferase and alanine aminotransferase = 2.5 x upper limit of normal; alkaline phosphatase = 2.5 x upper limit of normal Exclusion Criteria: - Prior radiation therapy to the abdomen that would overlap with the treatment field - Prior surgical resection of pancreatic tumor - Receiving any approved or investigational anti-cancer agent other than those provided for in this study - Uncontrolled or active gastric or duodenal ulcer disease within 30 days of dosing - Residual or ongoing =Grade 3 toxicity from chemotherapy - Contraindication to IV contrast that can't be managed with pre-medication - Concurrent participation in another interventional clinical trial or use of another investigational agent within 30 days of consent (concurrent non-interventional trials are eligible) - Uncontrolled intercurrent illness including but not limited to, symptomatic congestive heart failure, unstable angina pectoris, renal failure, cardiac arrhythmia, stroke, or psychiatric illness that would limit compliance with treatment - Second primary malignancy within the last 5 years, unless treated definitively and/or low risk in the judgement of the treating investigator - Known history of HIV or active hepatitis B/C (patients who have been vaccinated for hepatitis B and do not have history of infection are eligible) - Known intolerance or hypersensitivity to study drug - Subjects who are allergic to amoxicillin/clavulanic acid, erythromycin and imipenem - Female subjects who are breastfeeding - Women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control for the entire study and for 30 days after last dose of MRx0518. A negative pregnancy test must be obtained within 14 days prior to start of treatment - Male subjects who are unwilling or unable to use an acceptable method of birth control for the entire study period and for 30 days after last dose of MRx0518 - Serious infection requiring systemic therapy - Use of systemic antibiotics within 2 weeks of start of study treatment - Has a known inability for intake of oral capsules |
Country | Name | City | State |
---|---|---|---|
United States | MD Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
4D pharma plc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes to microbiome | The microbiome profile of faecal, urine, tumour and duodenum samples will be analysed for changes using the MicroDx platform | Baseline to 6 months post completion of radiation | |
Other | Tumour immune infiltration | Optional biopsies and resection specimens will be assessed for changes in tumour immune infiltrates | Baseline to Surgery | |
Other | Landscape of immune and stromal cells | Optional biopsy and resection specimens will be catalogued for the landscape of immune and stromal cells | Baseline to Surgery | |
Other | Changes in Circulating Tumour Cells | Blood samples will be assessed for presence of circulating tumour cells, circulating tumour DNA and/or circulating immune cells | Baseline to 6 months post completion of radiation | |
Other | Genomic changes | Whole exome sequencing and transcriptome sequencing from tumour and blood samples will be performed | Baseline to 6 months post completion of radiation | |
Primary | To assess the safety of MRx0518 in combination with hypofractionated preoperative radiation through the collection of adverse events | Adverse events will be assessed as per CTCAE v5.0 | Up to 1 year post completion of radiation | |
Secondary | Major pathologic response | Major pathologic response is defined as <5% viable cells in resected tumour specimen | At time of surgery | |
Secondary | Tumour infiltrating lymphocytes (TILs) | Changes in TILs from optional baseline biopsy to resected tumour specimen will be assessed. | Baseline to Surgery | |
Secondary | Overall Survival (OS) | OS is defined as the duration from the start of study treatment until death due to any cause | 12 months post radiation | |
Secondary | Progression Free Survival (PFS) | PFS is defined as the duration from the start of study treatment until disease progression or death | 12 months post radiation | |
Secondary | Local Control | Local control is defined as absence of progression at the primary site and will be assessed with imaging | 6 months post radiation | |
Secondary | Distant Control | Distant control is defined as absence of progression at any site other than the primary site and will be assessed with imaging | 6 months post radiation | |
Secondary | Margin status | The margin status of the tumour at the time of surgery will be assessed | At time of surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|